What is the half-life of Tesamorelin?

Tesamorelin has an approximate elimination half-life of 30 min. Very short-acting — protocols dose 1–2× a day.

How long does Tesamorelin stay in your system?

Roughly 97% of a dose has cleared after five half-lives — about ~3 h for Tesamorelin. That is the window that matters for washouts, bloodwork and surgery.

How is Tesamorelin taken?

Tesamorelin is typically administered by the subcutaneous route. Approved: 1–2 mg subcutaneous daily, evening dose.

What are the risks of Tesamorelin?

IGF-1 rise can affect glucose and joint comfort Avoid with active cancer or pituitary issues Expensive; off-label use is unsupervised

Tesamorelin

egrifta

GHRH analog — visceral-fat reduction. FDA-approved for HIV lipodystrophy. Protocol with measurable markers.

Half-life: 30 min
Out of system: ~3 h
Route: Subcutaneous
Level: Intermediate

Very short-acting — protocols dose 1–2× a day. After the last dose, roughly 97% has cleared in ~3 h (five half-lives) — the window that matters for washouts, bloodwork and surgery.

What Tesamorelin is used for

GHRH analog approved for HIV lipodystrophy — proven visceral-fat reduction
Cleanest GH-axis intervention with regulatory backing
Reported sleep + recovery improvements

How it's typically used

Approved: 1–2 mg subcutaneous daily, evening dose.

What to watch for

IGF-1 rise can affect glucose and joint comfort
Avoid with active cancer or pituitary issues
Expensive; off-label use is unsupervised

Common questions

What is the half-life of Tesamorelin?: Tesamorelin has an approximate elimination half-life of 30 min. Very short-acting — protocols dose 1–2× a day.
How long does Tesamorelin stay in your system?: Roughly 97% of a dose has cleared after five half-lives — about ~3 h for Tesamorelin. That is the window that matters for washouts, bloodwork and surgery.
How is Tesamorelin taken?: Tesamorelin is typically administered by the subcutaneous route. Approved: 1–2 mg subcutaneous daily, evening dose.
What are the risks of Tesamorelin?: IGF-1 rise can affect glucose and joint comfort Avoid with active cancer or pituitary issues Expensive; off-label use is unsupervised

About Performance & GH

What they are: Growth-hormone secretagogues and related performance compounds. Rather than supplying GH, they push your pituitary to release more of its own in a pulse.
How they're run: Subcutaneous injection, most often at night on an empty stomach so the pulse lands with natural sleep-driven GH release.
What to watch: Water retention, tingling hands, and hunger swings are the common early signs. Raising GH raises IGF-1 — worth tracking on bloodwork, and a reason to avoid these with any cancer history.

Full guide

Tesamorelin: A Tracking Guide for Visceral-Fat Protocols

What tesamorelin is, how protocols are structured, what to measure if you want to evaluate effects on visceral fat, energy, and sleep.

Other performance & gh

Peptid AI is an educational and self-tracking tool — not a medical service, and not a vendor. Nothing here is medical advice, a prescription, or an endorsement. Doses reflect what is commonly reported in research literature; they are not recommendations. Many compounds listed are experimental, not approved for human use, and/or controlled substances that are illegal to possess without a prescription in many countries. Always consult a qualified physician before starting, changing, or stopping any protocol.